CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
Adenocarcinoma
/ genetics
Aged
Aged, 80 and over
Carcinoma, Transitional Cell
/ genetics
Cyclin-Dependent Kinases
/ genetics
Disease Progression
Fatal Outcome
Gene Amplification
Genes, erbB-2
Genes, p53
Humans
Kidney Neoplasms
/ genetics
Male
Prostatic Neoplasms
/ genetics
Urinary Bladder Neoplasms
/ genetics
CDK12 amplification
DNA repair gene
ERBB2
prostate cancer
urothelial carcinoma
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
28
08
2020
revised:
19
09
2020
accepted:
24
09
2020
pubmed:
11
10
2020
medline:
30
12
2020
entrez:
10
10
2020
Statut:
ppublish
Résumé
Cyclin-dependent kinase 12 (CDK12), one of the key factors associated with DNA damage response pathways, is located on chromosome 17 proximal to Erb-B2 receptor tyrosine kinase 2 (ERBB2). In this report, CDK12 and ERBB2 coamplification was detected by targeted next-generation sequencing in two urothelial carcinomas. The staining intensity of the CDK12 and human epidermal growth factor receptor-2 proteins was associated with the prognosis of each urothelial carcinoma case. Our results suggest that CDK12 coamplification with ERBB2 might be associated with tumor aggressiveness and contribution to cancer pathogenesis. Therapies targeting CDK12 should be developed for these patients.
Identifiants
pubmed: 33038052
doi: 10.1111/cas.14672
pmc: PMC7734002
doi:
Substances chimiques
CDK12 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinases
EC 2.7.11.22
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
4652-4655Subventions
Organisme : Japan Urological Association Research Grant
ID : N/A
Organisme : Grant-in-Aid for Scientific Research
ID : #20H03817
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Cancer Res. 2002 Nov 1;62(21):6240-5
pubmed: 12414653
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Cancer Treat Rev. 2016 Nov;50:83-88
pubmed: 27662623
Mol Cancer Ther. 2018 Jan;17(1):306-315
pubmed: 29133620
Nucleic Acids Res. 2017 Jun 20;45(11):6698-6716
pubmed: 28334900
JCO Precis Oncol. 2020;4:370-381
pubmed: 32462107
Cancer Sci. 2020 Dec;111(12):4652-4655
pubmed: 33038052
Cell Div. 2017 Oct 27;12:7
pubmed: 29090014
N Engl J Med. 2020 Jun 18;382(25):2419-2430
pubmed: 32469182
Oncologist. 2019 Apr;24(4):444-448
pubmed: 30541755
Nature. 2016 May 25;534(7605):55-62
pubmed: 27251275
Nature. 2018 Dec;564(7734):141-145
pubmed: 30487607
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
EMBO Rep. 2019 Oct 4;20(10):e48058
pubmed: 31468695